At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 607 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared With Methotrexate Alone for the Treatment of Patients With Early Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating Infliximab for Rheumatoid Arthritis. Completed, enrolled 607 participants.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of infliximab (Remicade) in patients with early rheumatoid arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Study CompletionApr 2003
First PostedOct 2005
TodayJul 2026
First PostedOct 12, 2005
Study CompletionApr 1, 2003
TodayJul 2, 2026
Posted 20.7 years ago
Interventions
Infliximabdrug